Drug intelligence / Profile preview

Stabilized kilnman trio

Development stage: Unknown
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Stabilized kilnman trio is a topical treatment regimen used in dermatology, specifically studied for the management of melasma. It is applied once daily to the face and has been evaluated in clinical trials as an alternative or adjunct to laser therapy. The precise composition and mechanism of action are not detailed in available sources, but it is described as a combination product ("trio") suggesting three active components formulated for stability and efficacy in treating hyperpigmentation disorders such as melasma[1][2].

Other names: Stabilized kilnman trio

Targets

GR (Glucocorticoid receptor)RXRA (Retinoid X receptor alpha)TYR (Tyrosinase)RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on Stabilized kilnman trio.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stabilized kilnman trio.

Explore the full profile